New Role for Glial Energy Metabolism in Addiction
Reports new study in Biological Psychiatry
Reports new study in Biological Psychiatry
Philadelphia, PA, June 9, 2016
Addiction may be viewed as a disorder of reward learning. To date, addiction research has focused on the molecular adaptations through which memories of exposure to abused substances are encoded and maintained by nerve cells.
However, glia, the non-neuronal supporting cells of the brain, have now been implicated in the consolidation of cocaine-related memories. Researchers, led by senior author Dr. Jie Shi, Professor of Clinical Pharmacology at Peking University in China, report these new findings in the current issue of Biological Psychiatry.
Glia play a number of roles that support nerve cells. For example, they take up energy substrates, like glucose and acetate, and metabolize these chemicals into lactate, which they then release. Nerve cells absorb this lactate and use it to fuel many cellular functions.
In their new paper, Shi and colleagues report that reactivation of cocaine memories in rats alters the expression of a protein that releases lactate from glia and enables nerve cells to take up lactate. The authors found that if they blocked lactate release by glia or uptake by nerve cells, they produced a long-lasting prevention of cocaine relapse in rodents.
These data indicate that cellular metabolic communication plays a critical role in addiction-related behaviors, which may have implications for new strategies to prevent cocaine addiction.
“This study paves the way toward regional and time-specific therapeutics for drug craving and relapse,” said Shi.
“This study suggests that glia provide a critical source of fuel that is necessary for addiction-related memories,” added Dr. John Krystal, Editor of Biological Psychiatry. “It broadens our view of the neurobiology of addiction to appreciate a role for the often-neglected supporting cells of the brain.”
Notes for editors
The article is "Inhibition of Lactate Transport Erases Drug Memory and Prevents Drug Relapse," by Yan Zhang, Yanxue Xue, Shiqiu Meng, Yixiao Luo, Jie Liang, Jiali Li, Sizhi Ai, Chengyu Sun, Haowei Shen, Weili Zhu, Ping Wu, Lin Lu, and Jie Shi (doi: 10.1016/j.biopsych.2015.07.007). It appears in Biological Psychiatry, volume 79, issue 11 (2016), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or email@example.com. Journalists wishing to interview the authors may contact Yan Zhang at +1 443 240 9396 or firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 140 Psychiatry titles and 10th out of 252 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2014 Impact Factor score for Biological Psychiatry is 10.255.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880